Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A

Response to PXT3003 on efficacy outcomes (Full Analysis Set, n = 80). Data are mean (s.d.) baseline and final values, and % (s.d.) of improvement for each treatment group and PLI. Differences between treatment groups were assessed by Analysis of Covariance (Ancova) on log-transformed values by adjus...

Full description

Bibliographic Details
Main Authors: Attarian, Shahram, Jean-Michel Vallat, Magy, Laurent, Funalot, Benoît, Pierre-Marie Gonnaud, Lacour, Arnaud, Péréon, Yann, Dubourg, Odile, Pouget, Jean, Micallef, Joëlle, Franques, Jérôme, Marie-Noëlle Lefebvre, Ghorab, Karima, Al-Moussawi, Mahmoud, Tiffreau, Vincent, Preudhomme, Marguerite, Magot, Armelle, Leclair-Visonneau, Laurène, Stojkovic, Tanya, Bossi, Laura, Lehert, Philippe, Gilbert, Walter, Bertrand, Viviane, Mandel, Jonas, Milet, Aude, Hajj, Rodolphe, Boudiaf, Lamia, Scart-Grès, Catherine, Nabirotchkin, Serguei, Guedj, Mickael, Chumakov, Ilya, Cohen, Daniel
Format: Text
Language:unknown
Published: figshare 2019
Subjects:
DML
Online Access:https://dx.doi.org/10.6084/m9.figshare.10037333
https://springernature.figshare.com/articles/Additional_file_4_Table_S4_of_Erratum_to_An_exploratory_randomised_double-blind_and_placebo-controlled_phase_2_study_of_a_combination_of_baclofen_naltrexone_and_sorbitol_PXT3003_in_patients_with_Charcot-Marie-Tooth_disease_type_1A/10037333
id ftdatacite:10.6084/m9.figshare.10037333
record_format openpolar
spelling ftdatacite:10.6084/m9.figshare.10037333 2023-05-15T16:01:56+02:00 Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A Attarian, Shahram Jean-Michel Vallat Magy, Laurent Funalot, Benoît Pierre-Marie Gonnaud Lacour, Arnaud Péréon, Yann Dubourg, Odile Pouget, Jean Micallef, Joëlle Franques, Jérôme Marie-Noëlle Lefebvre Ghorab, Karima Al-Moussawi, Mahmoud Tiffreau, Vincent Preudhomme, Marguerite Magot, Armelle Leclair-Visonneau, Laurène Stojkovic, Tanya Bossi, Laura Lehert, Philippe Gilbert, Walter Bertrand, Viviane Mandel, Jonas Milet, Aude Hajj, Rodolphe Boudiaf, Lamia Scart-Grès, Catherine Nabirotchkin, Serguei Guedj, Mickael Chumakov, Ilya Cohen, Daniel 2019 https://dx.doi.org/10.6084/m9.figshare.10037333 https://springernature.figshare.com/articles/Additional_file_4_Table_S4_of_Erratum_to_An_exploratory_randomised_double-blind_and_placebo-controlled_phase_2_study_of_a_combination_of_baclofen_naltrexone_and_sorbitol_PXT3003_in_patients_with_Charcot-Marie-Tooth_disease_type_1A/10037333 unknown figshare https://dx.doi.org/10.1186/s13023-016-0463-6 Creative Commons Attribution 4.0 International https://creativecommons.org/licenses/by/4.0/legalcode cc-by-4.0 CC-BY Biochemistry Medicine Neuroscience Pharmacology Biotechnology 39999 Chemical Sciences not elsewhere classified FOS Chemical sciences Science Policy Text article-journal Journal contribution ScholarlyArticle 2019 ftdatacite https://doi.org/10.6084/m9.figshare.10037333 https://doi.org/10.1186/s13023-016-0463-6 2021-11-05T12:55:41Z Response to PXT3003 on efficacy outcomes (Full Analysis Set, n = 80). Data are mean (s.d.) baseline and final values, and % (s.d.) of improvement for each treatment group and PLI. Differences between treatment groups were assessed by Analysis of Covariance (Ancova) on log-transformed values by adjusting for baseline values. Estimates were provided as mean percentage change over baseline (90 % CI). Dose-effect was tested through Spearman’s rank correlation. P-values are one-tailed. CMTNS = Charcot-Marie-Tooth Neuropathy Score; ONLS = Overall Neuropathy Limitations Scale; 6MWT = 6-Minute Walk Test; 9HPT = 9-Hole Peg Test; CMAP = Amplitudes of Compound Muscle Action Potentials; MCV = Motor Conduction Velocity; DML = Distal Motor Latency; SNAP = Amplitudes of Sensory Nerve Action Potentials; SCV = Sensitive Conduction Velocity; VAS = Visual Analog Scale; CGI = Clinical Global Impression. (DOC 168 kb) Text DML DataCite Metadata Store (German National Library of Science and Technology) Charcot ENVELOPE(139.017,139.017,-69.367,-69.367)
institution Open Polar
collection DataCite Metadata Store (German National Library of Science and Technology)
op_collection_id ftdatacite
language unknown
topic Biochemistry
Medicine
Neuroscience
Pharmacology
Biotechnology
39999 Chemical Sciences not elsewhere classified
FOS Chemical sciences
Science Policy
spellingShingle Biochemistry
Medicine
Neuroscience
Pharmacology
Biotechnology
39999 Chemical Sciences not elsewhere classified
FOS Chemical sciences
Science Policy
Attarian, Shahram
Jean-Michel Vallat
Magy, Laurent
Funalot, Benoît
Pierre-Marie Gonnaud
Lacour, Arnaud
Péréon, Yann
Dubourg, Odile
Pouget, Jean
Micallef, Joëlle
Franques, Jérôme
Marie-Noëlle Lefebvre
Ghorab, Karima
Al-Moussawi, Mahmoud
Tiffreau, Vincent
Preudhomme, Marguerite
Magot, Armelle
Leclair-Visonneau, Laurène
Stojkovic, Tanya
Bossi, Laura
Lehert, Philippe
Gilbert, Walter
Bertrand, Viviane
Mandel, Jonas
Milet, Aude
Hajj, Rodolphe
Boudiaf, Lamia
Scart-Grès, Catherine
Nabirotchkin, Serguei
Guedj, Mickael
Chumakov, Ilya
Cohen, Daniel
Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A
topic_facet Biochemistry
Medicine
Neuroscience
Pharmacology
Biotechnology
39999 Chemical Sciences not elsewhere classified
FOS Chemical sciences
Science Policy
description Response to PXT3003 on efficacy outcomes (Full Analysis Set, n = 80). Data are mean (s.d.) baseline and final values, and % (s.d.) of improvement for each treatment group and PLI. Differences between treatment groups were assessed by Analysis of Covariance (Ancova) on log-transformed values by adjusting for baseline values. Estimates were provided as mean percentage change over baseline (90 % CI). Dose-effect was tested through Spearman’s rank correlation. P-values are one-tailed. CMTNS = Charcot-Marie-Tooth Neuropathy Score; ONLS = Overall Neuropathy Limitations Scale; 6MWT = 6-Minute Walk Test; 9HPT = 9-Hole Peg Test; CMAP = Amplitudes of Compound Muscle Action Potentials; MCV = Motor Conduction Velocity; DML = Distal Motor Latency; SNAP = Amplitudes of Sensory Nerve Action Potentials; SCV = Sensitive Conduction Velocity; VAS = Visual Analog Scale; CGI = Clinical Global Impression. (DOC 168 kb)
format Text
author Attarian, Shahram
Jean-Michel Vallat
Magy, Laurent
Funalot, Benoît
Pierre-Marie Gonnaud
Lacour, Arnaud
Péréon, Yann
Dubourg, Odile
Pouget, Jean
Micallef, Joëlle
Franques, Jérôme
Marie-Noëlle Lefebvre
Ghorab, Karima
Al-Moussawi, Mahmoud
Tiffreau, Vincent
Preudhomme, Marguerite
Magot, Armelle
Leclair-Visonneau, Laurène
Stojkovic, Tanya
Bossi, Laura
Lehert, Philippe
Gilbert, Walter
Bertrand, Viviane
Mandel, Jonas
Milet, Aude
Hajj, Rodolphe
Boudiaf, Lamia
Scart-Grès, Catherine
Nabirotchkin, Serguei
Guedj, Mickael
Chumakov, Ilya
Cohen, Daniel
author_facet Attarian, Shahram
Jean-Michel Vallat
Magy, Laurent
Funalot, Benoît
Pierre-Marie Gonnaud
Lacour, Arnaud
Péréon, Yann
Dubourg, Odile
Pouget, Jean
Micallef, Joëlle
Franques, Jérôme
Marie-Noëlle Lefebvre
Ghorab, Karima
Al-Moussawi, Mahmoud
Tiffreau, Vincent
Preudhomme, Marguerite
Magot, Armelle
Leclair-Visonneau, Laurène
Stojkovic, Tanya
Bossi, Laura
Lehert, Philippe
Gilbert, Walter
Bertrand, Viviane
Mandel, Jonas
Milet, Aude
Hajj, Rodolphe
Boudiaf, Lamia
Scart-Grès, Catherine
Nabirotchkin, Serguei
Guedj, Mickael
Chumakov, Ilya
Cohen, Daniel
author_sort Attarian, Shahram
title Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A
title_short Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A
title_full Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A
title_fullStr Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A
title_full_unstemmed Additional file 4: Table S4. of Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A
title_sort additional file 4: table s4. of erratum to: an exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (pxt3003) in patients with charcot-marie-tooth disease type 1a
publisher figshare
publishDate 2019
url https://dx.doi.org/10.6084/m9.figshare.10037333
https://springernature.figshare.com/articles/Additional_file_4_Table_S4_of_Erratum_to_An_exploratory_randomised_double-blind_and_placebo-controlled_phase_2_study_of_a_combination_of_baclofen_naltrexone_and_sorbitol_PXT3003_in_patients_with_Charcot-Marie-Tooth_disease_type_1A/10037333
long_lat ENVELOPE(139.017,139.017,-69.367,-69.367)
geographic Charcot
geographic_facet Charcot
genre DML
genre_facet DML
op_relation https://dx.doi.org/10.1186/s13023-016-0463-6
op_rights Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
cc-by-4.0
op_rightsnorm CC-BY
op_doi https://doi.org/10.6084/m9.figshare.10037333
https://doi.org/10.1186/s13023-016-0463-6
_version_ 1766397604969578496